PBAC's latest decision on Rosuvastatin calcium: Recommended with restriction (2006). Considered for For use in patients that meet the criteria set out in the General Statement for Lipid Lowering Drugs. Note: Doses higher than 20 mg per day should be used with caution.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2006
Submissions
1
2006 → 2006
Eligible population
patients that meet the criteria set out in the General Statement for Lipid Lowering Drugs. Note: Doses higher than 20 mg per day should be used with caution.
Therapy area
Cardiovascular
Evidence base
Meta-analysis
Key trials
SOLAR, MERCURY II, STELLAR, URANUS, ANDROMEDA, DISCOVERY, PULSAR, RADAR, LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study, ARIES, POLARIS, COMETS, DISCOVERY, CORALL
Comparator
atorvastatin
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated by design